Cellular responses to Plasmodium falciparum major surface antigens and their relationship to human activities associated with malaria transmission

American Journal of Tropical Medicine and Hygiene

Volumn 60, Issue 4, 1999, Pages 674-679

  Carvalho, Luzia H ^a   Fontes, Cor Jesus F ^b   Krettli, Antoniana U ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PARASITE ANTIGEN;

ADOLESCENT; ADULT; AGRICULTURAL WORKER; ARTICLE; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOREACTIVITY; INFECTION RISK; LIFESTYLE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MINER; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; RISK FACTOR;

EID: 0032926163     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.60.674     Document Type: Article

References (38)

1. Nussenzweig RS, Zavala F, 1997. A malaria vaccine based on a sporozoite antigen. N Engl J Med 336: 128-130.
2. Siddiqui WA, Tam LQ, Kramer KJ, Hui GS, Yamaga KM, Chang SP, Chang EB, Kali SC, 1987. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA 84: 3014-3018.
3. Etlinger HM, Caspers P, Matile H, Schoenfield HJ, Stueber D, Takacs B, 1991. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect Immun 59: 3498-3503.
4. Holder AA, Freeman RR, 1984. The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J Exp Med 160: 624-629.
5. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hui GS, 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite protein 1 protects Aotus monkeys against malaria. Infect Immun 64: 253-261.
6. Nussenzweig RS, Long CA, 1994. Malaria vaccines: multiple targets. Science 265: 1381-1383.
7. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillessen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM, 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257-259.
8. Ballou WR, Sherwood JA, Neva FA, Gordon DM, Wirtz RA, Wasserman GF, Diggs CL, Hoffman SL, Hollingdale MR, Hockmeyer WT, Schneider I, Young JF, Reeve P, Chulay JD, 1987. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet i: 1277-1281.
9. Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C, Brown G, Anders R, Coppel R, Woodrow G, Pye D, Sorenson F, Gillessen D, Matile H, Reber-Liske R, 1995. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and sexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg 53: 423-431.
10. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, Lachance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, Hauser P, Voet P, Sadoff JC, Ballow WR, 1995. Safety, immunogenicity, and efficacy of a recombinant produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171: 1576-1585.
11. Stoute JA, Slaqui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M, Ballow WR, Cohen JD, 1997. A preliminary evaluation of a recorabinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. New Engl J Med 336: 86-91.
12. Deane LM, 1986. Malaria vectors in Brazil. Mem Inst Oswaldo Cruz 81 (suppl 2): 5-14.
13. Marques AC, 1987. Human migration and the spread of malaria in Brazil. Parasitol Today 3: 166-170.
14. Tauil P, 1992. Malaria control - multisectorial approach. Mem Inst Oswaldo Cruz 87: 349-350.
15. Castillo-Salgado C, 1992. Epidemiological risk stratification of malaria in the Americas. Mem Inst Oswaldo Cruz 87 (suppl 3): 115-120.
16. Sawyer D, 1993. Economic and social consequences of malaria in new colonization projects in Brazil. Soc Sci Med 37: 1131-1136.
17. Camargo LMA, Dal Colletto GMD, Ferreira MU, Gurgel SM, Escobar AL, Marques A, Krieger H, Carmargo EP, Pereira-Silva LH, 1996. Hypoendemic malaria in Rondonia (Brazil, western Amazon region): seasonal variation and risk groups in an urban locality. Am J Trop Med Hyg 55: 32-38.
18. Carvalho LH, Fontes, CJF, Fernandes AAM, Marinuzzi HC, Krettli AU, 1997. Cross-reactive cellular immune response to circumsporozoite proteins of Plasmodium vivax and P. falciparum in malaria-exposed individuals. Parasite Immunol 19: 47-59.
19. Fontes CJF, Bathurst I, Krettli AU, 1991. Plasmodium vivax sporozoite antibodies in individuals exposed during a single malaria outbreak in a non-endemic area. Am J Trop Med Hyg 44: 28-33.
20. Braga EM, Fontes CJF, Krettli AU, 1998. Persistence of humoral responses against sporozoite and blood-stage malaria antigens seven years after a brief exposure to Plasmodium vivax. J Infect Dis 177: 1132-1135.
21. Marques AC, 1993. Dados epidemiolögicos de malária na Amazônia, por município, referente a 1992. Rev Soc Bras Med Trop 26: 43-59.
22. Dame JB, Williams, JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, Lee Maloy W, Haynes JD, Schneider I, Roberts D, Sanders GS, Reddy EP, Diggs CL, Miller LH, 1984. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225: 593-599.
23. Chang SP, Kramer KJ, Yamaga KM, Kato A, Case SE, Siddiqui WA, 1988. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp 195) of the Uganda-Palo Alto isolate. Exp Parasitol 67: 1-11.
24. Hui GSN, Ghang SP, Gibson H, Hashimoto A, Hashiro C, Barr PJ, Kotani S, 1991. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. (1991). J Immunol 147: 3935-3941.
25. Troye-Blomberg M, Romero P, Patarroyo ME, Bjorkman A, Perlmann P, 1984. Regulation of the immune response in Plasmodium falciparum malaria. III. Proliferative response to antigen in vitro and subset composition of T cells from patients with acute infection or from immune donors. Clin Exp Immunol 58: 380-387.
26. Riley EM, Andersson G, Otoo LN, Jepsen S, Greenwood BM, 1988. Cellular immune responses to Plasmodium falciparum antigens in Gambian children during and after an acute attack of falciparum malaria. Clin Exp Immunol 73: 17-22.
27. Zimmerman RH, Voorham J, 1997, Use of insecticide-impregnated mosquito nets and other impregnated materials for malaria control in the Americas. Rev Panam Salud Publica 2: 18-25.
28. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM, 1997. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65: 1606-1614.
29. Good MF, Pombo D, Quakyi IA, Riley EM, Houghten RA, Menon A, Ailing DW, Berzofsky JA, Miller LH, 1988. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 85: 1199-1203.
30. Beck HP, Felger I, Kabintik S, Tavul L, Genton B, Alexander N, Bhatia KK, Al-Yaman F, Hii J, Alpers M, 1994. Assessment of the humoral and cell-mediated immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in highly endemic malarious areas of Papua New Guinea. Am J Trop Med Hyg 51: 356-364.
31. Doolan DL, Beck HP, Good MF, 1994. Evidence for limited activation of distinct CD4+ T cell subsets in response to the Plasmodium falciparum circumsporozoite protein in Papua New Guinea. Parasite Immunol 16: 129-136.
32. Udhayakumar V, Shi YR Kumar S, Jue DL, Wohlhueter RM, Lal AA, 1994. Antigenic diversity in the circumsporozoite protein of Plasmodium falciparum abrogates cytotoxic-T-cell recognition. Infect Immun 62: 1410-1413.
33. Kwiatkowski D, Marsh K, 1997. Development of a malaria vaccine. Lancet 350: 1696-1701.
34. Gilbert SC, Plebanski M, Gupta S, Morris J, Cox M, Aidoo M, Kwiatkowski D, Greenwood BM, Whittle HC, Hill AV, 1998. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279: 1173-1177.
35. Branquinho MS, Lagos CBP, Rocha RM, Natal D, Barata JMS, Cochrane AH, Nardin E, Nussenzweig RS, Kloetzel JK, 1993. Anophelines in the state of Acre, Brazil, infected with Plasmodium falciparum, P. vivax, the variant P. vivax VK247 and P. malariae. Trans R Soc Trop Med Hyg 87: 391-394.
36. Rosales T, Guilherme L, Chiarella J, Marin ML, Rosales C, Melo CP, Goldberg AC, Kalil J, 1992. Human leukocyte A and B antigen, gene and haplotype frequencies in the population of the city of São Paulo in Brazil. Braz J Med Biol Res 25: 39-47.
37. Schlesinger L, Arevalo M, Simon V, Lopez M, Munoz C, Hernandez A, Carreno P, Belmar J, White A, Haffner-Cavaillon N, 1995. Immune depression induced by protein calorie malnutrition can be suppressed by lesioning central noradrenaline systems. J Neuroimmunol 57: 1-7.
38. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, Schonfeld HJ, Holder AA, Greenwood BM, 1992. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14: 321-337.